Dimitrova Dimana, Choudhry Vidita, Broder Christopher C
Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Methods Mol Biol. 2009;525:491-8, xiii. doi: 10.1007/978-1-59745-554-1_25.
Interest in the potential of monoclonal antibodies (mAbs) to serve as therapeutic agents has surged in the past decade with a major emphasis on human viral diseases. There has been much attention in this area directed towards the human immunodeficiency virus type-1 (HIV-1) and promising research developments have emerged on the inhibition of HIV-1 infection by mAbs and the identification of several highly conserved neutralizing epitopes. More recently, potent fully-human neutralizing mAbs have been developed against a variety of important human viral disease agents including the paramyxoviruses Hendra virus and Nipah virus, and human or humanized mAbs have been developed against severe acute respiratory syndrome coronavirus (SARS CoV), and West Nile virus, among others. Most of these more recently developed antiviral mAbs have come from the use of antibody phage-display technologies and the implementation of simplified, inexpensive yet efficient methods, for expressing and purifying the initially selected fragment antibodies is of prime importance in further facilitating this area of research.
在过去十年中，对单克隆抗体（mAb）作为治疗剂的潜力的兴趣激增，主要集中在人类病毒性疾病上。该领域对人类免疫缺陷病毒1型（HIV-1）给予了大量关注，并且在单克隆抗体抑制HIV-1感染以及鉴定几种高度保守的中和表位方面出现了有前景的研究进展。最近，已经开发出针对多种重要人类病毒病原体的强效全人源中和单克隆抗体，包括副粘病毒亨德拉病毒和尼帕病毒，并且已经开发出针对严重急性呼吸综合征冠状病毒（SARS-CoV）和西尼罗河病毒等的人源或人源化单克隆抗体。这些最近开发的抗病毒单克隆抗体大多来自抗体噬菌体展示技术的应用，并且实施简化、廉价但高效的方法来表达和纯化最初选择的片段抗体对于进一步推动该研究领域至关重要。
